AU2002211379A1 - Compositions and methods for treatment of cystic fibrosis - Google Patents

Compositions and methods for treatment of cystic fibrosis

Info

Publication number
AU2002211379A1
AU2002211379A1 AU2002211379A AU1137902A AU2002211379A1 AU 2002211379 A1 AU2002211379 A1 AU 2002211379A1 AU 2002211379 A AU2002211379 A AU 2002211379A AU 1137902 A AU1137902 A AU 1137902A AU 2002211379 A1 AU2002211379 A1 AU 2002211379A1
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
cystic fibrosis
cystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211379A
Inventor
William Reenstra
Ronald C. Rubenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2002211379A1 publication Critical patent/AU2002211379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
AU2002211379A 2000-10-04 2001-10-04 Compositions and methods for treatment of cystic fibrosis Abandoned AU2002211379A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23789900P 2000-10-04 2000-10-04
US60237899 2000-10-04
PCT/US2001/030897 WO2002028348A2 (en) 2000-10-04 2001-10-04 Compositions and methods for treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
AU2002211379A1 true AU2002211379A1 (en) 2002-04-15

Family

ID=22895704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211379A Abandoned AU2002211379A1 (en) 2000-10-04 2001-10-04 Compositions and methods for treatment of cystic fibrosis

Country Status (3)

Country Link
US (1) US20020115619A1 (en)
AU (1) AU2002211379A1 (en)
WO (1) WO2002028348A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
CA2376400A1 (en) * 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
EP1291015A1 (en) * 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004064742A2 (en) * 2003-01-17 2004-08-05 Uab Research Foundation Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms
AU2004227915A1 (en) * 2003-03-31 2004-10-21 John F. Engelhardt Pharmico-gene theraphy of epithelial sodium channel associated disoders
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
KR20160067985A (en) 2005-11-08 2016-06-14 버텍스 파마슈티칼스 인코포레이티드 Heterocyclic modulators of ATP-binding cassette transporters
US20090017062A1 (en) * 2006-04-28 2009-01-15 Iowa Research Foundation Iowa Centers For Enterpri Methods and compounds to alter virus infection
CN104447716A (en) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Modulators of CFTR
US8709709B2 (en) 2007-05-18 2014-04-29 Luoxis Diagnostics, Inc. Measurement and uses of oxidative status
ES2627188T3 (en) * 2007-05-18 2017-07-27 Aytu Bioscience, Inc. Measurement and uses of the oxidative state
EP2190850A4 (en) * 2007-07-03 2011-03-09 Univ British Columbia Small molecule correctors of deltaf508 cftr trafficking
EP2639224B1 (en) 2007-12-07 2016-08-24 Vertex Pharmaceuticals Incorporated Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
EP3683218A1 (en) 2007-12-07 2020-07-22 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011137427A2 (en) * 2010-04-30 2011-11-03 The Johns Hopkins University Compositions and methods for treating pulmonary conditions
JP5834319B2 (en) 2011-02-28 2015-12-16 アイトゥ バイオサイエンス インコーポレイテッドＡｙｔｕ ＢｉｏＳｃｉｅｎｃｅ，Ｉｎｃ． Apparatus for measuring redox potential
AU2013249126B2 (en) 2012-04-19 2015-10-01 Aytu Bioscience, Inc. Multiple layer gel
ES2656321T3 (en) 2012-05-17 2018-02-26 I.E.R.F.C. European Institute For Cystic Fibrosis Research Combined therapy for cystic fibrosis
CA2847665A1 (en) 2012-10-23 2014-04-23 Raphael Bar-Or Methods and systems for measuring and using the oxidation-reduction potential of a biological sample
RU2016122882A (en) 2013-11-12 2017-12-19 Вертекс Фармасьютикалз Инкорпорейтед METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
CA2968130C (en) 2014-11-18 2022-08-16 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
MA43735A (en) 2016-03-07 2018-11-28 Univ Iowa Res Found AAV MEDIATED EXPRESSION USING SYNTHETIC PROMOTER AND ACTIVATOR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy

Also Published As

Publication number Publication date
WO2002028348A2 (en) 2002-04-11
US20020115619A1 (en) 2002-08-22
WO2002028348A3 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2002211379A1 (en) Compositions and methods for treatment of cystic fibrosis
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001233081A1 (en) Composition for treatment of stress
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
IL161667A0 (en) Method and composition to treat cystic fibrosis
AU2001286983A1 (en) Method of treatment
AU2002231206A1 (en) Treatment of depression
AU2962400A (en) Cleaner composition and method of use thereof
AU6185698A (en) Methods and compositions for treating cystic fibrosis
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001242302A1 (en) Method of treating phenylketonuria and means therefor
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2001262177A1 (en) Method of treatment
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU2002355432A1 (en) Kavalactone compositions and methods of use
AU2001253560A1 (en) Methods of treatment
AU1943501A (en) Methods of treating inflammation and compositions therefor
AUPQ876400A0 (en) Compositions and method of using them